Evidence map›Paper›PMID 29483213›Full record

ArticleMolecular cancer therapeutics2018

Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.

Jing-Hung Wang, Alexis V Forterre, Jinjing Zhao, Daniel O Frimannsson, Alain Delcayre, Travis J Antes, Bradley Efron, Stefanie S Jeffrey, Mark D Pegram, A C Matin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 172 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Applications of mRNA Delivery in Cancer Immunotherapy.International journal of nanomedicine · 2025
    Review
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jing-Hung WangDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.
Alexis V ForterreDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.
Jinjing ZhaoDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.
Daniel O FrimannssonDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.
Alain DelcayreExoThera LLC, Menlo Park, California.
Travis J AntesSystems Biosciences, Palo Alto, California.
Bradley EfronDepartment of Statistics, Stanford University, Stanford, California.
Stefanie S JeffreyDepartment of Surgery, Stanford University School of Medicine, Stanford, California.
Mark D PegramDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
A C MatinDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California. a.matin@stanford.edu.
Stanford University · USStanford Medicine · USMeta (United States) · USSystem Biosciences (United States) · US

Funding

HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapyUH3TR000902 · NCATS · STANFORD UNIVERSITY · PI MATIN, AC · 2016 to 2017
$2.0M
HER2-targeted exosomal delivery of therapeutic mRNA for enzyme pro-drug therapyUH2TR000902 · NCATS · STANFORD UNIVERSITY · PI MATIN, AC · 2013 to 2015
$1.6M
NCATS NIH HHS UH2 TR000902NCATS NIH HHS UH3 TR000902
6 · The paper itself

Abstract

This paper deals with specific targeting of the prodrug/enzyme regimen, CNOB/HChrR6, to treat a serious disease, namely HER2

Indexed as

Xenograft Model Antitumor AssaysAnimalsBreast NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesExtracellular VesiclesFemaleHumansMCF-7 CellsMice, Inbred BALB CMice, NudeOxazinesProdrugsRNA, MessengerSingle-Chain AntibodiesTumor Burden6-chloro-9-nitro-5-oxo-5H-benzo(a)phenoxazineErb-b2 Receptor Tyrosine KinasesOxazinesProdrugsRNA, MessengerSingle-Chain Antibodies

Identifiers

PMID29483213
PMCPMC5932266
OpenAlexW2792159629

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.